MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders
maybefalse/E+ via Getty Images MediciNova (NASDAQ:MNOV) said it will get a patent from the Canadian Intellectual Property Office which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) to treat hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia — certain types of metabolic disorders. The patent maturing from this allowed patent application is expected to expire no earlier … Read more